No specifically targeted-treatment against the SARS-CoV-2 virus is available to-date. In separate randomized clinical studies, as a research group, we are currently focusing on inhaled nitric oxide gas (iNO), a pulmonary vasodilator which has shown antiviral activity against Coronavirus during the 2003 SARS outbreak.
However, in the current global health threat scenario, it might not be feasible to conduct appropriately designed interventional studies in every location. Observational data from a large dataset generated by a consortium of international institutions might help provide useful information and aid in the management of the crisis.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
We designed a data collection strategy focusing on COVID-19 patients admitted to the ICU due to critical illness. Data can be entered in the registry both prospectively and retrospectively, provided a reliable source of clinical data is available within the center. The project has been approved by the Partners Institutional Review Board (Protocol #: 2020P000760).
The purpose of this study is to deploy a global, secure, user-friendly, adaptive, and reliable registry platform aimed at gathering insight into how critically ill patients due to COVID-19 are currently being treated worldwide.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 200 participants
Primary Purpose: Treatment
Actual Study Start Date: March 21, 2020
Estimated Study Completion Date: March 21, 2022
* Additional criteria apply. Please speak with the study team for further information.
Thanks to a fast-paced turnover of data analysis and sharing we aim at providing the ICU community reliable information on important endpoints, such as:
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.